Sign in
Not yet recruitingNo phase

A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice

Key facts

Who runs it
Implantica CE Reflux Ltd.
Where
Germany and Spain5 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
500 people, planned
Started
15 Sept 2025
Expected to end
1 Aug 2035
Type of study
Interventional
Treatments tested
  • RefluxStop™ implantation
Record updated
4 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Willing and able to provide informed consent and to participate in the registry study
  • Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older
  • Documented GERD present for ≥ 6 months. Typical symptoms are defined as heartburn
  • 24-hour pH or impedance pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be < 4 for ≥ 4.5% of total time during a 24-hour monitoring) and/or total reflux episodes >55 or weekly acid >26 for > 5 seconds, all measured 5 cm above LES)
  • Suitable to undergo general anaesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator

Who cannot take part

  • History of bariatric surgery wherein the stomach fundus has been extirpated
  • Known sensitivity or allergies to silicone materials
  • Subjects that are unable to comply with the registry requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement)
  • Hiatal Hernia larger than 8 cm
  • Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed. Patients with substantially weak peristalsis (manometry DCI value 100-200) in esophagus measured during manometry would continue the simplified contrast swallow x-ray to perform a simplified two-hour gastric emptying contrast swallow
  • Female subjects who are pregnant
  • Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry procedure (as outlined in the IFU)

Where is this trial?

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the treatment of subjects suffering from GERD.

Read full original descriptionShow less

Following surgery, patients will have follow-ups visits at 3 and 6 months and annually up to 7 years.

The group in the trial

  • Single arm: interventionOther group

    Single arm registry: all enrolled patients will be implanted with RefluxStopTM

    Treatment: RefluxStop™ implantation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Post-market Registry Study Based on Standard Clinical Care to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
Record updated
4 June 2025